Immunic
IMUX
75 hedge funds and large institutions have $72.1M invested in Immunic in 2026 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 20 increasing their positions, 7 reducing their positions, and 14 closing their positions.
549% more call options, than puts
Call options by funds: $526K | Put options by funds: $81K
186% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 7
155% more capital invested
Capital invested by funds: $28.3M → $72.1M (+$43.8M)
129% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 14
29% more funds holding
Funds holding: 58 → 75 (+17)
0.71% more ownership
Funds ownership: 4.26% → 4.98% (+0.71%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$4.03M |
| 2 |
6CM
683 Capital Management
New York
|
+$2.19M |
| 3 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$2.1M |
| 4 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$1.79M |
| 5 |
Morgan Stanley
New York
|
+$1.07M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Focus Partners Wealth
Boston,
Massachusetts
|
-$2.29M |
| 2 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$1.68M |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$282K |
| 4 |
Squarepoint
New York
|
-$188K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$174K |
IMUX Hedge Fund Activity: Q1 2026 in Review
75 of the 8,192 institutional investors tracked by Wall St. Rank reported a position in Immunic (IMUX) for Q1 2026, worth a combined $72.1M — up 155% from $28.3M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new IMUX positions and 14 closed out — a net gain of 18 holders — while 20 added to existing stakes and 7 trimmed.
The largest buyer was Soleus Capital Management, opening a new position worth an estimated $4.03M. The largest seller was Focus Partners Wealth, exiting entirely with an estimated $2.29M sold.
- 75 institutional investors held Immunic (IMUX) as of Q1 2026, up from 58 in Q4 2025.
- Funds reported $72.1M of Immunic stock for Q1 2026, up 155% quarter-over-quarter.
- 32 funds opened new Immunic positions in Q1 2026 and 14 closed out, a net change of +18 holders.
- The largest Immunic buyer in Q1 2026 was Soleus Capital Management, an estimated $4.03M added.
- The largest Immunic seller in Q1 2026 was Focus Partners Wealth, an estimated $2.29M sold.
Based on aggregated 13F filings for Q1 2026.